Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a synthetic cyclic peptide somatostatin analogue with high binding affinity for multiple somatostatin receptor subtypes, notably somatostatin receptor type 5, and it reduces adrenocorticotropic hormone secretion from pituitary corticotroph adenomas. The molecule is available as an immediate release subcutaneous formulation and as a long acting intramuscular depot formulation for extended exposure. From a pharmaceutical perspective pasireotide requires peptide-specific manufacturing controls including careful oxidation and deamidation management, validated peptide mapping and mass spectrometry characterization, and aseptic sterile processing for the parenteral products. Clinically relevant pharmacology includes inhibition of hormone secretion through G protein coupled receptor signaling and measurable effects on glucose regulation that reflect reduced insulin and incretin release.
The impurity profile for pasireotide is dominated by peptide-related substances formed through common peptide degradation pathways including deamidation of Asn/Gln residues, oxidation of susceptible residues such as methionine, N and C terminal truncations, peptide bond cleavage, isomerization and low-level aggregation; positional isomers and process-related impurities such as truncated synthesis byproducts can also be present. Typical quality control specifications used by manufacturers and consistent with peptide guidance documents commonly limit individual related peptide impurities to approximately 0.1 to 1.0 percent of total peak area by validated reversed-phase HPLC methods, with the sum of related substances frequently controlled to about 3.0 percent or less at release; specified known degradants that affect potency or safety are often assigned tighter limits in the 0.1 to 0.5 percent range. Analytical characterization of these impurities relies on orthogonal techniques such as RP-HPLC, LC-MS/MS peptide mapping, and SEC for aggregates, and impurity limits and identification requirements are set in line with ICH Q3A, Q3B and Q6B principles and product-specific validation data.
Pasireotide binds somatostatin receptors on pituitary corticotroph cells, with especially high affinity for receptor subtype 5, and decreases ACTH secretion leading to reduced cortisol production; it is used to control hypercortisolism in patients with Cushing’s disease who are not surgical candidates or who have persistent disease after surgery.
Pasireotide is a synthetic somatostatin analogue, a peptide class drug acting as a somatostatin receptor agonist, often categorized pharmacologically as a somatostatin receptor ligand or peptide hormone analog.
